Categories: News

BioCryst to Report First Quarter 2021 Financial Results on May 6

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A telephone replay of the call will be available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID # 2660434.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Staff

Recent Posts

Eyemart Express Teams Up with “The Jennifer Hudson Show” to Encourage Young Readers

Partnership launches a summer digital series that celebrates the joy of reading DALLAS, June 24,…

3 hours ago

ZEISS Solves Industry Challenges at Tech Days Event

ZEISS Industry Tech Days brings together manufacturers across five states to show how advanced metrology…

3 hours ago

A Glimpse Into the Future of Mass Spectrometry: Game-Changing Technologies and Transformative Trends Unveiled at ASMS 2025

ARLINGTON, Va., June 24, 2025 /PRNewswire/ -- Behind the doors of the ASMS 2025 conference, held…

4 hours ago

Circulogene Launches LungLifeAI® Nationally Through Primary Care Channel

PENSACOLA, Fla., June 24, 2025 /PRNewswire/ -- Circulogene, a leading provider of precision diagnostics for…

4 hours ago

LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading On TSX Venture Exchange

Toronto, Ontario--(Newsfile Corp. - June 24, 2025) - LevelJump Healthcare Corp. - (TSXV: JUMP) ("LevelJump" or the "Company") is…

8 hours ago

AllianceHCM Appoints Alan Primeaux as Chief Executive Officer to Propel Next Phase of Growth

HOUSTON, June 24, 2025 /PRNewswire/ -- AllianceHCM, one of the nation's leading privately held providers…

9 hours ago